{"name":"Ocera Therapeutics","slug":"ocera-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AST-120","genericName":"AST-120","slug":"ast-120","indication":"Other","status":"marketed"},{"name":"OCR-002 IV Solution","genericName":"OCR-002 IV Solution","slug":"ocr-002-iv-solution","indication":"Other","status":"phase_1"},{"name":"OCR-002 Oral Solution","genericName":"OCR-002 Oral Solution","slug":"ocr-002-oral-solution","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AST-120","genericName":"AST-120","slug":"ast-120","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OCR-002 IV Solution","genericName":"OCR-002 IV Solution","slug":"ocr-002-iv-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OCR-002 Oral Solution","genericName":"OCR-002 Oral Solution","slug":"ocr-002-oral-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9MWkt6RHdabWN3em9RRnY1bHpiVDg4RllsbVZhXzBfZkE2VkpxWlpBQWJBSDdQTGl6aUE3UFBydmY1RGh5Q3doblItUFJoWk9aQ0hFNDh5UTlvWHItejRVM1hGaml0cVplaHlmVFVfMUVTQUtfM0xaTTVn?oc=5","date":"2024-10-30","type":"pipeline","source":"Straits Research","summary":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033 - Straits Research","headline":"Overt Hepatic Encephalopathy Market Size, Global Trends, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQeHpYeFBUbGJoRVpVYjNsd05DSDczRlZVRzJWSlF3M21jbGl3YlBiYXgwdHhDNmsyYmRPM1pQb1A0ZE1hczNENnl3QS1PRDJYSkFpcGliWkZseHoxcnJUbXRYV05fR3AxT3dITGZuSmUzbGFXMUpaTDRmMHJoM19zTTEzQWliZw?oc=5","date":"2023-04-09","type":"pipeline","source":"Dignity Memorial","summary":"Keith Anderson Obituary - Henderson, NV - Dignity Memorial","headline":"Keith Anderson Obituary - Henderson, NV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOenUzLWhHZTNGYk9SLUFjWHk4NGdnQ0o0bGh5el9fQ2d3QXNSTHFuVzlURXdrSVBGZnVURjhreEJOV1N1NkMyLWJOZVlTYkxqdl9HNnRUb0NvdWZja3FBaWhfWi00ek1kcndjUzNmWF9HRVVubUlsc2dpdjI3Zkw4MGxRZkY3dWJpNUl6ajZwaDNndmN5aENfOHhZOVp2Wk0?oc=5","date":"2018-08-23","type":"pipeline","source":"BioPharma Dive","summary":"Mallinckrodt gets CRL for newborn jaundice drug - BioPharma Dive","headline":"Mallinckrodt gets CRL for newborn jaundice drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQbWRkcThkd24yZHRnWWtka1NaMlpCeUdwZEk2UXZzVDhqcktQLWJLY3hjMVh6Q20xWVlsYjFoTV9fVEtTcjlQVTdIQ3RBeHRXTG5QTGFYb1M0WVpwTjZaakg4aXZMQmQyWlpFbGFiMTF4QVktMFplSVhDc0xnazVuWldkbDJrUWpNem1lWWJ1dWI?oc=5","date":"2018-04-03","type":"pipeline","source":"Fierce Biotech","summary":"Pharma vet Stan Bukofzer joins Depomed as CMO/CSO - Fierce Biotech","headline":"Pharma vet Stan Bukofzer joins Depomed as CMO/CSO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNa0VUR0VRQl9sNE0wVU1Zbnh6c09PU3VUNFFZbURUSFhFYnphTEhMb3lxa3Fvc0VuTFh4bWlMYXJjQ2YtNzNSSFZUYUpka0d0R24wYW5nU2dhcklCNzZFVmVNWXJ2Z01zWVpwYmpUODJlMkNNUmtsdUdkR01BN0tSMzh6cTMtTnVmSE0tMmRNeWdacTZ1a2c?oc=5","date":"2017-12-26","type":"deal","source":"BioPharma Dive","summary":"Mallinckrodt builds pipeline through $1.2B Sucampo deal - BioPharma Dive","headline":"Mallinckrodt builds pipeline through $1.2B Sucampo deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPS3kyVnpXdWJqcTY4WjV3YUNUWndfM2hOMm1Mb0J6dDN3bXEwaWV4cWIzcTJJbF84YkFGMDVETE42TDN4Yy1yX1JZRE9YVEFkOXpzVXdoMktIUU5QaVg2RHprbEZKSVowZUo5MWN1bXZxSmgxa3d0VzZRelcteURYYjZDUVNWYnQ1SDUteW9ILVIwWDUxRmg1NnRDX0NWclJobVVEZVlpVmNzV2FWZkZKSUttWDEwbFd1OHM1NERuaTBGbjNOTlhkM3o5UDBZRWVDQXBZTGxoSXM5cXROeWVvTlB6RU9neFNBa0tIazM0TGc1QkNDcEtXYi1GUVRWLUxtaHp5RlpUb0dqN0dza2FOSENmTTZUMzFYMjlzQ0NzT1Q5VGtFZGt4Qko3NA?oc=5","date":"2017-12-11","type":"pipeline","source":"PR Newswire","summary":"Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy - PR Newswire","headline":"Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOMmJYWUNFV3Z5WWJ3ZDJNRXNMTWp6bURHZTZtdDU0ckJmTGE3ZVRnX0NYTHVlcnY0UlBMYmZuVDhXc1UxbU84clVBV1E1NS1paExqTGFFc01TT0M3Uy1JVkhscU9BMGRESFAxOFNfNGFZM210WW42eVpzRUdEeFVQOHZENms3RWNsX08xVjJ0UFlmOEh4YWdhRGgzaEdYb2NxWGFvYTctQUoxeGFmZEIyakkzOFpOSkVkNGVXSEZSNTJyanR1NjFtTnBfUFpfcXozdWFhYXItblpPeUx0RjlKTnN2UVJCLXdWQnkyMlc3eHlwTzl3SWJLQl9ablVHd1d2Y3JENFllRXVxZUd5T3g4Ni11ZUlpc2Rp?oc=5","date":"2017-11-02","type":"deal","source":"PR Newswire","summary":"Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy - PR Newswire","headline":"Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPdWgyaDdfZzhnb242MzFXSkpXSEs4cnlvTVBpTDBiQzJMazFMcHlkZnJVWGxYa25qWUtHLW5fVzdwWFNZSjNnSTF5ZXBLWHRsUWduakg3S0JlQzNINmVaRkRtYXcwNHVyZzVKNXQ5MmV0RHd1U2ZIS091OXcyQ3VSX0Z2d0x6T2FCUHBfUG9BSFVTTXFi?oc=5","date":"2013-07-16","type":"deal","source":"Contract Pharma","summary":"Ocera Therapeutics Completes Tranzyme Merger - Contract Pharma","headline":"Ocera Therapeutics Completes Tranzyme Merger","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}